Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. Singer M, et al. Among authors: bernard gr. JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. JAMA. 2016. PMID: 26903338 Free PMC article.
Activated protein C for severe sepsis.
Ely EW, Bernard GR, Vincent JL. Ely EW, et al. Among authors: bernard gr. N Engl J Med. 2002 Sep 26;347(13):1035-6. doi: 10.1056/NEJM200209263471315. N Engl J Med. 2002. PMID: 12324564 No abstract available.
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Vincent JL, et al. Among authors: bernard gr. Crit Care Med. 2003 Mar;31(3):834-40. doi: 10.1097/01.CCM.0000051515.56179.E1. Crit Care Med. 2003. PMID: 12626993 Clinical Trial.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Among authors: bernard gr. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
352 results